

# Paulo Roberto Abro Ferreira

## List of Publications by Citations

**Source:**

<https://exaly.com/author-pdf/9507116/paulo-roberto-abrao-ferreira-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

151  
citations

6  
h-index

11  
g-index

21  
ext. papers

190  
ext. citations

3.3  
avg, IF

2.24  
L-index

#	Paper	IF	Citations
20	Imbalance between endothelial progenitors cells and microparticles in HIV-infected patients naive for antiretroviral therapy. <i>Aids</i> , <b>2011</b> , 25, 1595-601	3.5	41
19	Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 976-83	13.4	20
18	Disease burden of chronic hepatitis C in Brazil. <i>Brazilian Journal of Infectious Diseases</i> , <b>2015</b> , 19, 363-8	2.8	15
17	Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study. <i>Brazilian Journal of Infectious Diseases</i> , <b>2014</b> , 18, 48-52	2.8	11
16	Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and S Paulo, Brazil. <i>Virology Journal</i> , <b>2013</b> , 10, 320	6.1	10
15	Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251048	3.7	8
14	Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients. <i>Hepatology International</i> , <b>2014</b> , 8, 83-93	8.8	6
13	Response predictors to treatment with pegylated interferon in chronic hepatitis B. <i>Brazilian Journal of Infectious Diseases</i> , <b>2010</b> , 14, 519-25	2.8	6
12	Association between IL28B gene polymorphisms and sustained virological response in patients coinfecting with HCV and HIV in Brazil. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 509-10	5.1	6
11	Full-length genomic sequence of hepatitis B virus genotype C2 isolated from a native Brazilian patient. <i>Memorias Do Instituto Oswaldo Cruz</i> , <b>2011</b> , 106, 495-8	2.6	4
10	Short communication: Evaluation of GB virus C/hepatitis G viral load among HIV type 1-coinfecting patients in S Paulo, Brazil. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 1301-4	1.6	4
9	Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP prevent COVID-19-related symptoms?. <i>Epidemiology and Infection</i> , <b>2020</b> , 148, e231	4.3	4
8	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138503	3.7	3
7	The interference of COVID-19 in the male reproductive system: Important questions and the future of assisted reproduction techniques. <i>Clinics</i> , <b>2020</b> , 75, e2183	2.3	3
6	Characteristics of an outpatient chronic hepatitis B virus infection cohort. <i>Einstein (Sao Paulo, Brazil)</i> , <b>2015</b> , 13, 189-95	1.2	2
5	The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study. <i>Brazilian Journal of Infectious Diseases</i> , <b>2015</b> , 19, 15-22	2.8	1
4	Hepatitis B viremia in HIV-coinfecting individuals under antiretroviral therapy. <i>Brazilian Journal of Infectious Diseases</i> , <b>2019</b> , 23, 441-450	2.8	1

- 3 Impact of In-Hospital infection with SARS-CoV-2 among Inpatients at a university hospital. *American Journal of Infection Control*, **2021**, 49, 1464-1468 3.8 0
- 2 Response predictors to treatment with pegylated interferon in chronic hepatitis B. *Brazilian Journal of Infectious Diseases*, **2010**, 14, 519-525 2.8
- 1 Baseline factors associated with death in a COVID-19 hospital cohort, Sao Paulo, 2020. *Revista De Saude Publica*, **2021**, 55, 76 2.4